Reclassifying marijuana as a less dangerous drug might only be the first step for Trump
Federal cannabis reclassification to Schedule III represents a landmark shift in medical cannabis policy with significant clinical implications. This regulatory change acknowledges cannabis's therapeutic potential while creating new pathways for research…
DOJ Schedule III cannabis order creates uncertainty for D.C.’s medical self-certification program
The DOJ Schedule III cannabis order creates regulatory uncertainty for D.C.’s medical self-certification program. This federal scheduling change may disrupt patient access to medical cannabis. Clinicians and patients must understand the implications of…
Federal Marijuana Rescheduling Could Trigger Obscure SC Law – Post and Courier
Federal marijuana rescheduling impact could activate dormant state medical cannabis laws in South Carolina. This change may expand patient access rapidly while creating regulatory uncertainty. Understanding these shifts is crucial for clinicians and…
Adriana E. Ramírez: Trump Administration’s Impact on Cannabis Scheduling
The 2026 cannabis federal scheduling changes directly influence medical access and research opportunities. These policy shifts under the Trump administration affect physician recommendations and patient care. Understanding 2026 cannabis federal…
Bridging the Regulatory Chasm in Investigator‐Initiated Cannabis Research
Investigator initiated cannabis research barriers limit clinical studies and evidence-based medicine. Regulatory challenges impede rigorous cannabis research needed for informed decisions. Understanding these barriers is key to advancing cannabis…